Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-04-17
2009-02-24
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S395000, C536S021000
Reexamination Certificate
active
07494975
ABSTRACT:
The present invention relates to an anti-HIV composition and to the method for producing it.The composition of the present invention comprises a polyanion and a molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein. The polyanion may be chosen, for example, from the group consisting of heparin, heparan sulphate, and a polyanion equivalent to heparin or to heparan sulphate. The molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein is a CD4 peptide or a derivative thereof.The present invention also relates to the use of said composition for producing a medicinal product, in particular a medicinal product intended for the treatment of AIDS.
REFERENCES:
patent: 2006/0121538 (2006-06-01), Vita et al.
patent: 0 249 390 (1987-12-01), None
patent: 0 332 952 (1989-09-01), None
patent: 0 355 905 (1989-09-01), None
patent: 92 04909 (1992-04-01), None
patent: 02 059146 (2002-08-01), None
http://redppoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi?CARD=APRD00068.txt, accessed online Jan. 5, 2008, pp. 1-3.
Dowd et al. B-Turn Phe n HIV-1 Env Binding Site of CD4 and CD4 Mimetic Miniprotein Enhances Env Binding Affinity but is Not Required for Activation of C0-Receptor/17b Site. Biochemistry. Jun. 4, 2002. vol. 41, pp. 7038-7046.
Martin et al. Engineering Novel Bioactive Mini-Proteins on Natrual Scaffolds. Tetrahedron 2000. vol. 56, pp. 9451-9460.
Witvrouw, M. et al. “Sulfated Polysaccharides Extracted from Sea Algae as Potential Antiviral Drugs”, Gen. Pharmac., vol. 29, No. 4, pp. 497-511, XP002056013 1997.
Moulard, Maxime et al. “Selective Interactions of Polyanions with Bases Surfaces on Human Immunodeficiency Virus Type 1 gp120”, Journal of Virology, vol. 74, No. 4, pp. 1948-1960, XP002226781 2000.
Sullivan, Nancy et al. “Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies”, Journal of Virology, vol. 72, No. 8, pp. 6332-6338, XP002226782 1998.
Harrop, Hilary A. et al. “Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding”, AIDS, vol. 8, No. 2, pp. 183-192, XP002226783 1994.
Chan, David C. et al. “HIV Entry and Its Inhibition”, Cell, vol. 93, pp. 681-684 1998.
Clapham, Paul R. “HIV and chemokines: ligands sharing cell-surface receptors”, Trends in Cell Biology, vol. 7, pp. 264-268 1997.
Michael, Nelson L. et al. “HIV-1 entry inhibitors: Evading the issue”, Nature Medicine, vol. 5, No. 7, pp. 740-742 1999.
Chan, David C. et al. “Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target”, Proc. Natl. Acad. Sci. vol. 95, pp. 15613-15617 1998.
Doms, Robert W. et al. “HIV-1 Membrane Fusion: Targets of Opportunity”, The Journal of Cell Biology, vol. 151, No. 2, pp. F9-F13 2000.
Schenten, Dominik et al. “Effects of Soluble CD4 on Simian Immunodeficiency Virus Infection of CD4-Positive and CD4-Negative Cells”, Journal of Virology, vol. 73, No. 7, pp. 5373-5380 1999.
Chen, Ji-Dai et al. “Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy”, Nature Medicine, vol. 3, No. 10, pp. 1110-1116 1997.
Oberlin, Estelle et al. “The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1”, Nature, vol. 382, pp. 833-835 1996.
Proudfoot, Amanda et al. “Chemokine Receptors—Future Therapeutic Targets for HIV?” Biochemical Pharmacology, vol. 57, pp. 451-463 1999.
Murakami, Tsutomu et al. “A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line-tropic HIV-1 Infection”, J. Exp. Med., vol. 186, No. 8, pp. 1389-1393 1997.
Mondor, Isabelle et al. “Human Immunodeficiency Virus Type 1 Attachment to HeLa CD4 Cells is CD4 Independent and gp120 Dependent and Requires Cell Surface Heparans”, Journal of Virology, vol. 72, No. 5, pp. 3623-3634 1998.
Roderiquez, Gregory et al. “Mediation of Human Immunodeficiency Virus Type 1 Binding by Interaction of Cell Surface Heparan Sulfate Proteoglycans with the V3 Region of Envelope gp120-gp41”, Journal of Virology, vol. 69, No. 4, pp. 2233-2239 1995.
Abrams, Donald I. et al. “Oral Dextran Sulfate (UA001) in the Treatment of the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex”, Annals of Internal Medicine, vol. 110, No. 3, pp. 183-188 1989.
Flexner, Charles et al. “Pharmacokinetics, Toxicity, and Activity of Intravenous Dextran Sulfate in Human Immunodeficiency Virus Infection”, Antimicrobial Agents and Chemotherapy, vol. 35, No. 12, pp. 2544-2550 1991.
Chernyak, Anatoly et al. “Conjugating oligosaccharides to proteins by squaric acid diester chemistry: rapid monitoring of the progress of conjugation, and recovery of the unused ligand”, Carbohydrate Research, vol. 330, pp. 479-486 2001.
Kuberan, B. et al. “Preparation and isolation of neoglycoconjugates using biotin-streptavidin complexes”, Glycoconjugate Journal, vol. 16, pp. 271-281 1999.
Najjam, Saloua et al. “Characterization of Human Recombinant Interleukin 2 Binding to Heparin and Heparan Sulfate Using an Elisa Approach”, Cytokine, vol. 9, No. 12, pp. 1013-1022 1997.
Dreef-Tromp, C.M. et al. “Biological Properties of Synthetic Glycoconjugate Mimics of Heparin Comprising Different Molecular Spacers”, Bioorganic and Medicinal Chemistry Letters, vol. 8, pp. 2081-2086 1998.
Grootenhuis, P.D. et al. “Rational Design of Synthetic heparin analogues with tailor-made coagulation factor inhibitory activity”, Nature Structural Biology, vol. 2, No. 9, pp. 736-739 1995.
Claudio Vita et al., “Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein”, PNAS. Nov. 9, 1999, vol. 96, No. 23, pp. 13091-13096.
Loïc Martin et al., “Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes”, www.nature.com
aturebiotechnology, Jan. 2003, vol. 21, pp. 71-76.
Lortat-Jacob Hugues
Sattentau Quentin
Vita Claudio
Vives Romain
Centre National de la Recherche Scientifique
Commissariat a l''Energie Atomique
Cordero Garcia Marcela M
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Tsang Cecilia
LandOfFree
Anti-HIV composition, production method thereof and medicament does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-HIV composition, production method thereof and medicament, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-HIV composition, production method thereof and medicament will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4071504